Chapter 1. FDA APPROVAL REQUIREMENT
- 1.01 Marketing New Drugs; General Requirements
- 1.02 Marketing New Drugs without FDA Approval
- 1.03 Application of New Drug Definition to Generic Products
- 1.04 Escaping New Drug Status
- 1.05 Determination of New Drug Status
- 1.06 FDA Enforcement Policy
Chapter 2. FULL NEW DRUG APPLICATIONS
- 2.01 Generally
- 2.02 New Drug Applications—Content
- 2.03 New Drug Applications—Procedure
- 2.04 Supplemental New Drug Applications
- 2.05 New Drug Applications—Withdrawal of Approval
- 2.06 New Drug Applications—Suspension of Approval
Chapter 3. ABBREVIATED NEW DRUG APPLICATIONS AND “505(b)(2) APPLICATIONS”
- 3.01 Generally
- 3.02 Abbreviated New Drug Applications under 505(j); Qualifying Drugs
- 3.03 Abbreviated New Drug Applications under 505(j); Contents
- 3.04 Abbreviated New Drug Applications under 505(j); Procedure
- 3.05 505(b)(2) Applications
Chapter 4. DELAYING APPROVAL OF COMPETITIVE PRODUCTS
Chapter 5. PUBLIC AVAILABILITY OF DRUG AND BIOLOGIC DATA
- 5.01 Pending Applications
- 5.02 Safety and Effectiveness Data
- 5.03 Information Concerning ANDA Approval Process
Chapter 6. POTENTIAL FOR GOVERNMENT COMPENSATION
Chapter 7. THE ORPHAN DRUG AMENDMENTS
- 7.01 Orphan Drug Designation
- 7.02 Orphan Drug Exclusivity
- 7.03 Other Benefits of Designation
Chapter 8. DEBARMENT AND CIVIL PENALTIES
- 8.01 Background
- 8.02 Overview
- 8.03 Debarment
- 8.04 Civil Penalties—GDEA
- 8.05 Civil Penalties—Other
- 8.06 Suspension of Right to Distribute
Chapter 9. FDA FRAUD POLICY
- 9.01 Generally
- 9.02 Applicability and Effect
- 9.03 Actions Required
- 9.05 Internal Reviews and Corrective Action Plans
- 9.06 Validity of the Fraud Policy
Chapter 10. EXPANDED ACCESS TO INVESTIGATIONAL DRUGS AND ACCELERATED APPROVALS
- 10.01 Background
- 10.02 Expanded Access to Investigational Drugs for Treatment Use
- 10.03 Expedited Approval Procedure
Chapter 11. EXPORT AND IMPORT REQUIREMENTS
- 11.01 Introduction
- 11.02 Export Requirements
- 11.03 Imports
Chapter 12. PRESCRIPTION DRUG AND BIOLOGIC USER FEES
- 12.01 Introduction
- 12.02 Types of User Fees
- 12.03 Waivers, Reductions, and Refunds
- 12.04 Failure to Pay Fees
- 12.05 Condition for Continuation of Fees
- 12.06 User Fee Invoicing
- 12.07 The Quid Pro Quo: FDA Commitments
- 12.08 Conclusion
Chapter 13. FDA APPROVAL OF BIOLOGIC DRUGS